Corcept Therapeutics to Start Phase 3 Trial of Relacorilant Plus Nab-Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer
June 06, 2022 08:00 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat...
Corcept Therapeutics Announces First Quarter Financial Results And Provides Corporate Update
May 05, 2022 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat...
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
April 28, 2022 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update...
Corcept Therapeutics Announces Appointment of Three Senior Leaders
April 07, 2022 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe...
Corcept Therapeutics Completes Enrollment in Phase 2 GRATITUDE Study of Miricorilant in Patients with Antipsychotic-Induced Weight Gain
April 04, 2022 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe...
Relacorilant Plus Nab-Paclitaxel Extends Survival in Women with Recurrent, Platinum-resistant Ovarian Cancer
March 30, 2022 16:05 ET
|
Corcept Therapeutics Incorporated
Addition of relacorilant to nab-paclitaxel reduces risk of death by 33 percent compared to treatment with nab-paclitaxel alone (p-value: 0.066), without increased side effectsExcluding patients (i)...
Corcept Therapeutics to Host Ovarian Cancer Program Update on Thursday, March 31, 2022
March 01, 2022 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will host an event for investors and analysts on Thursday, March 31, 2022...
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2021 Audited Financial Results and Provides Corporate Update
February 15, 2022 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial stage company engaged in the discovery, development and sale of drugs to treat...
Corcept Therapeutics to Announce Fourth Quarter and Full-year 2021 Financial Results, Provide Corporate Update and Host Conference Call
February 08, 2022 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full-year 2021 financial results and provide...
Corcept Therapeutics Announces Final Results of Previously Announced Tender Offer
December 20, 2021 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) (“Corcept”), a commercial-stage company engaged in the discovery and development of drugs to...